132 related articles for article (PubMed ID: 32407745)
1. Development and in vivo evaluation of Irinotecan-loaded Drug Eluting Seeds (iDES) for the localised treatment of recurrent glioblastoma multiforme.
Gawley M; Almond L; Daniel S; Lastakchi S; Kaur S; Detta A; Cruickshank G; Miller R; Hingtgen S; Sheets K; McConville C
J Control Release; 2020 Aug; 324():1-16. PubMed ID: 32407745
[TBL] [Abstract][Full Text] [Related]
2. Preclinical impact of bevacizumab on brain and tumor distribution of irinotecan and temozolomide.
Goldwirt L; Beccaria K; Carpentier A; Idbaih A; Schmitt C; Levasseur C; Labussiere M; Milane A; Farinotti R; Fernandez C
J Neurooncol; 2015 Apr; 122(2):273-81. PubMed ID: 25794638
[TBL] [Abstract][Full Text] [Related]
3. Local administration of irinotecan using an implantable drug delivery device stops high-grade glioma tumor recurrence in a glioblastoma tumor model.
Abdelnabi D; Lastakchi S; Watts C; Atkins H; Hingtgen S; Valdivia A; McConville C
Drug Deliv Transl Res; 2024 Feb; ():. PubMed ID: 38319555
[TBL] [Abstract][Full Text] [Related]
4. Hot melt extruded and injection moulded disulfiram-loaded PLGA millirods for the treatment of glioblastoma multiforme via stereotactic injection.
McConville C; Tawari P; Wang W
Int J Pharm; 2015 Oct; 494(1):73-82. PubMed ID: 26235918
[TBL] [Abstract][Full Text] [Related]
5. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Brandes AA; Tosoni A; Basso U; Reni M; Valduga F; Monfardini S; Amistà P; Nicolardi L; Sotti G; Ermani M
J Clin Oncol; 2004 Dec; 22(23):4779-86. PubMed ID: 15570079
[TBL] [Abstract][Full Text] [Related]
6. Nanocomposite formulation for a sustained release of free drug and drug-loaded responsive nanoparticles: an approach for a local therapy of glioblastoma multiforme.
Erthal LCS; Shi Y; Sweeney KJ; Gobbo OL; Ruiz-Hernandez E
Sci Rep; 2023 Mar; 13(1):5094. PubMed ID: 36991081
[TBL] [Abstract][Full Text] [Related]
7. Advanced interstitial chemotherapy combined with targeted treatment of malignant glioma in rats by using drug-loaded nanofibrous membranes.
Tseng YY; Su CH; Yang ST; Huang YC; Lee WH; Wang YC; Liu SC; Liu SJ
Oncotarget; 2016 Sep; 7(37):59902-59916. PubMed ID: 27494894
[TBL] [Abstract][Full Text] [Related]
8. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH
Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605
[TBL] [Abstract][Full Text] [Related]
9. Post-resection treatment of glioblastoma with an injectable nanomedicine-loaded photopolymerizable hydrogel induces long-term survival.
Zhao M; Danhier F; Bastiancich C; Joudiou N; Ganipineni LP; Tsakiris N; Gallez B; Rieux AD; Jankovski A; Bianco J; Préat V
Int J Pharm; 2018 Sep; 548(1):522-529. PubMed ID: 30017818
[TBL] [Abstract][Full Text] [Related]
10. Concurrent delivery of carmustine, irinotecan, and cisplatin to the cerebral cavity using biodegradable nanofibers: In vitro and in vivo studies.
Tseng YY; Wang YC; Su CH; Yang TC; Chang TM; Kau YC; Liu SJ
Colloids Surf B Biointerfaces; 2015 Oct; 134():254-61. PubMed ID: 26209775
[TBL] [Abstract][Full Text] [Related]
11. Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer.
Shapira-Furman T; Serra R; Gorelick N; Doglioli M; Tagliaferri V; Cecia A; Peters M; Kumar A; Rottenberg Y; Langer R; Brem H; Tyler B; Domb AJ
J Control Release; 2019 Feb; 295():93-101. PubMed ID: 30605703
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.
Hofland KF; Hansen S; Sorensen M; Engelholm S; Schultz HP; Muhic A; Grunnet K; Ask A; Costa JC; Kristiansen C; Thomsen C; Poulsen HS; Lassen U
Acta Oncol; 2014 Jul; 53(7):939-44. PubMed ID: 24456504
[TBL] [Abstract][Full Text] [Related]
13. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic efficacy of aldoxorubicin in an intracranial xenograft mouse model of human glioblastoma.
Marrero L; Wyczechowska D; Musto AE; Wilk A; Vashistha H; Zapata A; Walker C; Velasco-Gonzalez C; Parsons C; Wieland S; Levitt D; Reiss K; Prakash O
Neoplasia; 2014 Oct; 16(10):874-82. PubMed ID: 25379024
[TBL] [Abstract][Full Text] [Related]
15. Formulation and in vitro evaluation of 17-allyamino-17-demethoxygeldanamycin (17-AAG) loaded polymeric mixed micelles for glioblastoma multiforme.
Saxena V; Hussain MD
Colloids Surf B Biointerfaces; 2013 Dec; 112():350-5. PubMed ID: 24012704
[TBL] [Abstract][Full Text] [Related]
16. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.
Brada M; Hoang-Xuan K; Rampling R; Dietrich PY; Dirix LY; Macdonald D; Heimans JJ; Zonnenberg BA; Bravo-Marques JM; Henriksson R; Stupp R; Yue N; Bruner J; Dugan M; Rao S; Zaknoen S
Ann Oncol; 2001 Feb; 12(2):259-66. PubMed ID: 11300335
[TBL] [Abstract][Full Text] [Related]
17. Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy.
Song S; Mao G; Du J; Zhu X
Drug Deliv; 2016 May; 23(4):1404-8. PubMed ID: 26203687
[TBL] [Abstract][Full Text] [Related]
18. Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.
Alshami J; Guiot MC; Owen S; Kavan P; Gibson N; Solca F; Cseh A; Reardon DA; Muanza T
Oncotarget; 2015 Oct; 6(32):34030-7. PubMed ID: 26423602
[TBL] [Abstract][Full Text] [Related]
19. Development of disulfiram-loaded poly(lactic-co-glycolic acid) wafers for the localised treatment of glioblastoma multiforme: a comparison of manufacturing techniques.
Zembko I; Ahmed I; Farooq A; Dail J; Tawari P; Wang W; Mcconville C
J Pharm Sci; 2015 Mar; 104(3):1076-86. PubMed ID: 25537972
[TBL] [Abstract][Full Text] [Related]
20. Brain Targeting by Liposome-Biomolecular Corona Boosts Anticancer Efficacy of Temozolomide in Glioblastoma Cells.
Arcella A; Palchetti S; Digiacomo L; Pozzi D; Capriotti AL; Frati L; Oliva MA; Tsaouli G; Rota R; Screpanti I; Mahmoudi M; Caracciolo G
ACS Chem Neurosci; 2018 Dec; 9(12):3166-3174. PubMed ID: 30015470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
